date:Apr 28, 2014
to continue to protect and build this valuable asset for both our nutraceutical and pharmaceutical businesses, said Henri Harland, president and CEO of Neptune. Neurological disorders, such as Alzheimers, are growing and new methods to prevent and treat such conditions using alternative treatments are continuously being sought out. In addition to Neptune, this new patent substantially benefits our subsidiary, NeuroBioPharm, as it continues to develop omega-3 phospholipid products for neurolog